Evidence map›Paper›PMID 36757527›Full record

ArticleJournal of neuro-oncology2023

Outcomes following management of relapsed pediatric posterior fossa ependymoma in the molecular era.

Armaan K Malhotra, Liana F Nobre, George M Ibrahim, Abhaya V Kulkarni, James M Drake, James T Rutka, Eric Bouffet, Michael D Taylor, Derek Tsang, Vijay Ramaswamy and 2 more

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review and update on pediatric ependymoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2023
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Armaan K MalhotraDivision of Neurosurgery, University of Toronto, Toronto, ON, Canada.
Liana F NobreNeuro-oncology Section, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.
George M IbrahimDivision of Pediatric Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada.
Abhaya V KulkarniDivision of Pediatric Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada.
James M DrakeDivision of Pediatric Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada.
James T RutkaDivision of Pediatric Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada.
Eric BouffetRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Michael D TaylorDivision of Pediatric Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada.
Derek TsangRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Vijay RamaswamyNeuro-oncology Section, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Peter B DirksDivision of Pediatric Neurosurgery, Hospital for Sick Children, Toronto, ON, Canada.
Michael C DewanDepartment of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN, USA. michael.dewan@vumc.org.
Hospital for Sick Children · CANeurological Surgery · USPrincess Margaret Cancer Centre · CAUniversity Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe overall survival and prognostic factors for children with multiply recurrent posterior fossa ependymoma are not well understood. We aimed to assess prognostic factors associated with survival for relapsed pediatric posterior fossa ependymoma.

methodsAn institutional database was queried for children with a primary diagnosis of posterior fossa ependymoma from 2000 to 2019. Kaplan-Meier survival analysis and Cox-proportional hazard regression were used to assess the relationship between treatment factors and overall survival.

resultsThere were 60 patients identified; molecular subtype was available for 56, of which 49 (87.5%) were PF-A and 7 (12.5%) were PF-B. Relapse occurred in 29 patients (48%) at a mean time of 24 months following primary resection. Median 50% survival was 12.3 years for all patients and 3.3 years following diagnosis of first relapsed disease. GTR was associated with significantly improved survival following primary resection (HR 0.373, 95% CI 0.14-0.96). Presence of recurrent disease was significantly associated with worse survival (p < 0.0001). At recurrent disease diagnosis, disseminated disease was a negative prognostic factor (HR 11.0 95% CI 2.7-44) while GTR at first relapse was associated with improved survival HR 0.215 (95% CI: 0.048-0.96, p = 0.044). Beyond first relapse, the impact of GTR was not significant on survival, though surgery compared to no surgery was favorable with HR 0.155 (95% CI: 0.04-0.59).

conclusionsDisseminated disease at recurrence and extent of resection for first relapsed disease were important prognostic factors. Surgery compared to no surgery was associated with improved survival for the multiply recurrent ependymoma cohort.

Indexed as

Brain NeoplasmsEpendymomaChildHumansKaplan-Meier EstimateNeoplasm Recurrence, LocalPrognosisNeuro-oncologyPediatricsPosterior fossa ependymomaPrognosisRecurrent ependymomaSurgery

Identifiers

PMID36757527
OpenAlexW4319656025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.